BioFocus DPI and Dart Neuroscience Sign Drug Discovery and Compound Management Agreements
News Dec 10, 2008
BioFocus DPI and Dart Neuroscience LLC (DNS) announced new collaboration agreements in drug discovery and compound management. Total potential value of the contracts for BioFocus DPI is €4.1 million over three years.
BioFocus DPI, the service division of Galapagos, will develop a cell-based assay for DNS’s drug discovery programs for brain disorders and perform high-throughput screening and hit expansion using BioFocus DPI’s compound collections. Furthermore, BioFocus DPI will carry out compound management for DNS over the next three years.
“This collaboration maximizes several key BioFocus DPI strengths: assay development and high-throughput screening as well as compound libraries and compound management,” said Onno van de Stolpe, CEO of Galapagos. “We are particularly pleased that our compound management facility in San Francisco continues to help us win new contracts and clients – we have seen strong progress in development of this business in 2008.”
“We are confident that BioFocus DPI’s integrated offering will contribute to advancing our drug discovery programs focused on various aspects of cognitive dysfunction,” added Tim Tully, Chief Scientific Officer of DNS.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018